Literature DB >> 25767169

Does ezetimibe modify clinical outcomes?

Ricky D Turgeon1, Kelly B Zarnke2, G Michael Allan3.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 25767169      PMCID: PMC4369637     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  8 in total

1.  Statin-induced diabetes: too sweet a deal?

Authors:  Ricky Turgeon; G Michael Allan
Journal:  Can Fam Physician       Date:  2013-07       Impact factor: 3.275

2.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Authors:  Anne B Rossebø; Terje R Pedersen; Kurt Boman; Philippe Brudi; John B Chambers; Kenneth Egstrup; Eva Gerdts; Christa Gohlke-Bärwolf; Ingar Holme; Y Antero Kesäniemi; William Malbecq; Christoph A Nienaber; Simon Ray; Terje Skjaerpe; Kristian Wachtell; Ronnie Willenheimer
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

3.  Simvastatin with or without ezetimibe in familial hypercholesterolemia.

Authors:  John J P Kastelein; Fatima Akdim; Erik S G Stroes; Aeilko H Zwinderman; Michiel L Bots; Anton F H Stalenhoef; Frank L J Visseren; Eric J G Sijbrands; Mieke D Trip; Evan A Stein; Daniel Gaudet; Raphael Duivenvoorden; Enrico P Veltri; A David Marais; Eric de Groot
Journal:  N Engl J Med       Date:  2008-03-30       Impact factor: 91.245

4.  Extended-release niacin or ezetimibe and carotid intima-media thickness.

Authors:  Allen J Taylor; Todd C Villines; Eric J Stanek; Patrick J Devine; Len Griffen; Michael Miller; Neil J Weissman; Mark Turco
Journal:  N Engl J Med       Date:  2009-11-15       Impact factor: 91.245

5.  Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.

Authors:  Christopher P Cannon; Robert P Giugliano; Michael A Blazing; Robert A Harrington; John L Peterson; Christine McCrary Sisk; John Strony; Thomas A Musliner; Carolyn H McCabe; Enrico Veltri; Eugene Braunwald; Robert M Califf
Journal:  Am Heart J       Date:  2008-09-02       Impact factor: 4.749

6.  Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study.

Authors:  George N Kouvelos; Eleni M Arnaoutoglou; Miltiadis I Matsagkas; Christina Kostara; Constantina Gartzonika; Eleni T Bairaktari; Haralampos J Milionis
Journal:  J Cardiovasc Pharmacol Ther       Date:  2012-05-09       Impact factor: 2.457

7.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

Authors:  C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins
Journal:  Lancet       Date:  2010-11-08       Impact factor: 79.321

8.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

Authors:  Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.